Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
86.42
+0.12 (0.14%)
Mar 9, 2026, 1:41 PM EDT - Market open
Mirum Pharmaceuticals Employees
As of December 31, 2025, Mirum Pharmaceuticals had 372 total employees, including 369 full-time and 3 part-time employees. The number of employees increased by 50 or 15.53% compared to the previous year.
Employees
372
Change (1Y)
50
Growth (1Y)
15.53%
Revenue / Employee
$1,401,376
Profits / Employee
-$62,804
Market Cap
5.21B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,769 |
| PTC Therapeutics | 991 |
| CRISPR Therapeutics AG | 393 |
| Immunovant | 362 |
| Apogee Therapeutics | 261 |
| CG Oncology | 142 |
| Protagonist Therapeutics | 132 |
| Scholar Rock Holding | 128 |
MIRM News
- 4 days ago - Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus - Business Wire
- 11 days ago - Mirum Pharmaceuticals, Inc. (MIRM) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update - Business Wire
- 13 days ago - Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
- 18 days ago - Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 - Business Wire
- 26 days ago - Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome - Business Wire
- 4 weeks ago - Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) - Business Wire